1. Home
  2. DVAX

DVAX

Dynavax Technologies Corporation

Logo Dynavax Technologies Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Founded: 1996 Country:
United States
United States
Employees: N/A City: EMERYVILLE
Market Cap: 1.5B IPO Year: 2004
Target Price: $25.00 AVG Volume (30 days): 1.8M
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.05 EPS Growth: N/A
52 Week Low/High: $10.06 - $15.15 Next Earning Date: 04-30-2024
Revenue: $232,284,000 Revenue Growth: -67.86%
Revenue Growth (this year): 26.45% Revenue Growth (next year): 20.63%

Share on Social Networks: